$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Is it true that after using ritexitinib, my hair grows but my hair doesn’t stop falling out?
2026-02-01 22:25:32
Check Details
Will Canafenib be included in medical insurance in 2025? Latest progress in medical insurance negotiations
2026-02-01 22:25:32
Check Details
Contraindications and precautions when using beclomethasone/formoterol/glycopyrrolate spray (Trimbow)
2026-02-01 22:25:32
Check Details
The English name and global market situation of axitinib/axitinib
2026-02-01 22:25:32
Check Details
Domestic price forecast of trametinib in 2025: Will patient burden be reduced?
2026-02-01 22:25:32
Check Details
The connection between Osimertinib, Osimertinib and Tagrisso
2026-02-01 22:25:32
Check Details
Can giritinib cure the disease? Analysis of efficacy and cure rate
2026-02-01 22:25:32
Check Details
Beclomethasone/formoterol/glycopyrrolate spray (Trimbow) analysis: drug characteristics and marketing status
2026-02-01 22:25:32
Check Details
What are the recommended usage and dosage of Pimitinib?
2026-02-01 22:25:32
Check Details
What are the medical insurance reimbursement conditions for Lynparza/Olaparib? Which patients are eligible for medical insurance?
2026-02-01 22:25:32
Check Details
Is venetoclax/venetoclax a targeted drug? What is the price and efficacy?
2026-02-01 22:25:32
Check Details
What is the current market price of ritexitinib? What is the price difference between different specifications?
2026-02-01 22:25:32
Check Details
1
2
...
1492
1493
1494
1495
1496
1497
1498
...
10226
10227
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
2
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
3
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
4
Asciminib (SCEMBLIX): STAMP Inhibitor Dosing Guide and Nomenclature Clarification for CML
5
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights
6
Cabergoline Medication Guide: Contraindications, Treatment Costs, and Safety Monitoring Essentials
7
Pemigatinib vs. Anlotinib: Key Differences Between FGFR-Targeted Therapy and Multi-Target Anti-Angiogenic Treatment
8
Enasidenib (IDHIFA): A Comprehensive Guide to Targeted Therapy for IDH2-Mutated Acute Myeloid Leukemia
9
Midostaurin vs. Gilteritinib: Key Differences in FLT3-Targeted AML Therapy
10
Lapatinib: A Targeted Anticancer Agent — Not Merely Symptom Relief
11
Filgotinib: Mechanism of Action and Clinical Applications Explained
12
Lapatinib: Proper Administration Guide and Key Precautions